Author:
Nishiyama Naotaka,Masumori Naoya
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference14 articles.
1. Santoni M, De Tursi M, Felici A et al (2013) Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 13:697–709
2. Hudes G, Carducci M, Tomczak P et al (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281
3. NCCN.org (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer Version3. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf . Accessed Jul 2016
4. Ljungberg B, Bensalah K (2016) The European Association of Urology (EAU) renal cell cancer (RCC) guidelines. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Renal-Cell-Carcinoma-2016.pdf . Accessed Jul 2016
5. Miyake H, Harada K, Kumano M et al (2014) Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan. Int J Clin Oncol. 19:679–685
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Temsirolimus;Reactions Weekly;2017-02